Efficacy and Safety of Oral Supplementation with Liposomal Iron in Non-Dialysis Chronic Kidney Disease Patients with Iron Deficiency

Nutrients. 2024 Apr 24;16(9):1255. doi: 10.3390/nu16091255.

Abstract

Introduction: Iron deficiency is common in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Oral iron supplementation is recommended in these patients, but it is associated with a higher incidence of gastrointestinal adverse reactions. Liposomal iron therapy has been proposed as a new iron formulation, improving iron bioavailability with less side effects; however, few data are available in patients with NDD-CKD.

Methods: We designed a single-arm pilot study to evaluate the efficacy of liposomal iron administered for six months in correcting iron deficiency (defined as serum ferritin < 100 ng/mL and/or transferrin saturation < 20%) in patients with NDD-CKD stages 1-5. The primary endpoints were the achievement of serum ferritin ≥ 100 ng/mL and transferrin saturation ≥ 20%. Secondary outcomes were hemoglobin (Hb) changes and the safety of liposomal iron.

Results: The efficacy population included 34/38 patients, who completed at least one visit after baseline. Liposomal iron increased the achievement of transferrin saturation targets from 11.8% at baseline to 50.0% at month 6 (p = 0.002), while no significant correction of serum ferritin (p = 0.214) and Hb was found (p = 0.465). When patients were stratified by anemia (Hb < 12 g/dL in women and Hb < 13 g/dL in men), a significant improvement of transferrin saturation was observed only in anemic patients (from 13.3 ± 5.8% to 20.2 ± 8.1%, p = 0.012). Hb values slightly increased at month 6 only in anemic patients (+0.60 g/dL, 95%CI -0.27 to +1.48), but not in those without anemia (+0.08 g/dL, 95%CI -0.73 to +0.88). In patients taking at least one dose of liposomal iron (safety population, n = 38), the study drug was discontinued in eight patients due to death (n = 2), a switch to intravenous iron (n = 2), and the occurrence of side effects (n = 4).

Conclusions: The use of liposomal iron in patients with NDD-CKD is associated with a partial correction of transferrin saturation, with no significant effect on iron storage and Hb levels.

Keywords: CKD; anemia; iron; iron deficiency; liposomal iron.

MeSH terms

  • Administration, Oral
  • Aged
  • Anemia, Iron-Deficiency* / blood
  • Anemia, Iron-Deficiency* / drug therapy
  • Anemia, Iron-Deficiency* / etiology
  • Dietary Supplements*
  • Female
  • Ferritins* / blood
  • Hemoglobins* / analysis
  • Hemoglobins* / metabolism
  • Humans
  • Iron Deficiencies
  • Iron* / administration & dosage
  • Iron* / blood
  • Liposomes*
  • Male
  • Middle Aged
  • Pilot Projects
  • Renal Insufficiency, Chronic* / complications
  • Transferrin* / metabolism
  • Treatment Outcome

Substances

  • Liposomes
  • Iron
  • Hemoglobins
  • Ferritins
  • Transferrin

Grants and funding

This research received no external funding.